Step 1: Store

Upon receipt, follow storage instructions on the SoftBox.

  • Protect TUDRIQEV from light and store in the original carton until use2
  • Store TUDRIQEV at −70°C to −90°C (−94°F to −130°F)2
  • Following receipt, follow storage instructions on the SoftBox and detailed handling instructions found inside the box3
Exploded view of the TUDRIQEV shipper, top to bottom: A, Shipper top cover; B, TUDRIQEV Receiving Instructions; C, Silver VIP TOP Panel; D, Dry Ice Filled Core Box; E, Product and/or Dry Ice Filled Core Box; F, Dry Ice Pellets; G, Shipper Divider; H, 8L CGT Ultra VIP Shipper.
Item Component Quantity
A Shipper top cover (may/may not include cutout for temperature monitor. Temperature monitor not part of shipment) 1
B TUDRIQEV Receiving Instructions 1
C Silver VIP TOP Panel 1
D Dry Ice Filled Core Box 1, ≥ 0.46 kg
E Product and/or Dry Ice Filled Core Box 3
F Dry Ice Pellets ≥ 9.8 kg
G Shipper Divider 1
H 8L CGT Ultra VIP Shipper (outer lids may/may not have cutout section for temperature monitor devices. Temperature monitor not part of shipment) 1
Step 2: Thaw2

Thaw vials inside the original carton immediately prior to administration using one of the following methods:

  • Room Temperature: Thaw at 15°C to 25°C (59°F to 77°F)
  • Refrigeration: Thaw at 2°C to 8°C (36°F to 46°F)

Do not refreeze TUDRIQEV after thawing.

  • 106 and 107 vials of TUDRIQEV may be stored at 2°C to 8°C (36°F to 46°F) for up to 2 days and 4 days, respectively
  • 106 and 107 vials of TUDRIQEV may be stored at room temperature at 15°C to 25°C (59°F to 77°F) for up to 12 hours and 24 hours, respectively

After thawing, TUDRIQEV is a colorless, translucent to opaque suspension and may contain visible, white to off-white, or colorless particles or fibers that may appear globular or amorphous. These particulates are inherent to the formulation.

Step 3: Prepare2

Avoid accidental exposure to TUDRIQEV by wearing appropriate personal protective equipment. Observe standard precautions when preparing and administering TUDRIQEV.

TUDRIQEV should be prepared by a healthcare professional experienced in the use of anticancer therapy.

  • Swirl gently, inspect vial; particles may be visible
  • If settlement occurs, resuspend by gently swirling; DO NOT shake
  • Using aseptic technique, withdraw the required dosage volume from the vial(s) into the syringe(s) to be used for administration
    • Select needles gauged between 17G and 27G based on the location and characteristics of the tumors to be injected. A higher needle gauge will allow for a smaller puncture in tissue and will reduce leakage of TUDRIQEV along the needle tract. A lower needle gauge is needed for fibrotic or deeper lesions
  • Administer TUDRIQEV within 2 hours of syringe preparation

Accidental exposure

If an accidental exposure to TUDRIQEV occurs (eg, touching or scratching the unprotected injection site or dressings), exposed individuals should clean the affected area with soap and water. If signs and symptoms of herpetic infection develop, exposed individuals should contact their healthcare provider for assessment and treatment as clinically warranted.

Step 4: Disinfect2

Always wear appropriate protective equipment when disinfecting surfaces to prevent accidental exposure.

Thoroughly disinfect all surfaces and equipment that came into contact with TUDRIQEV (including spills).

  • Use a broad spectrum virucidal agent, such as 70% isopropanol or 1% sodium hypochlorite
Step 5: Dispose2

Always wear appropriate protective equipment when disposing of materials to prevent accidental exposure.

Dispose of the used vials and all materials that may have come in contact with TUDRIQEV as biohazardous waste.

This includes:

  • Used vials
  • Syringes and needles
  • Gloves and any other protective gear
  • Dressing materials or other contaminated items

Resources

Access resources designed to support you, your practice, and your patients.

Indication & Important Safety Information

Indication

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Important Safety Information

Warnings and Precautions
Accidental exposure of TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients.

Herpetic infection or reactivation: Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted.

Injection procedure complications: Complications related to injection procedure have occurred, including hemorrhage, infection, and visceral injury. Patients should be monitored for signs and symptoms of visceral injury (eg, pneumothorax) during and after TUDRIQEV administration and managed according to clinical practice.

Immune-mediated events: In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab.

Adverse Reactions
Most common non-laboratory adverse reactions reported in more than 10% of patients were fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain.

Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1).

Drug Interactions
Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

Special Populations
Advise females and males of reproductive potential to use effective contraception during treatment with TUDRIQEV and for 90 days after the last dose.

Please report any adverse event or product quality complaint related to a Replimune product by calling 1-877-375-0095.

Please see full Prescribing Information.

Indication

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Important Safety Information

Warnings and Precautions
Accidental exposure of TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients.

Herpetic infection or reactivation: Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted.

Injection procedure complications: Complications related to injection procedure have occurred, including hemorrhage, infection, and visceral injury. Patients should be monitored for signs and symptoms of visceral injury (eg, pneumothorax) during and after TUDRIQEV administration and managed according to clinical practice.

Immune-mediated events: In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab.

Adverse Reactions
Most common non-laboratory adverse reactions reported in more than 10% of patients were fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain.

Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1).

Drug Interactions
Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

Special Populations
Advise females and males of reproductive potential to use effective contraception during treatment with TUDRIQEV and for 90 days after the last dose.

Please report any adverse event or product quality complaint related to a Replimune product by calling 1-877-375-0095.

Please see full Prescribing Information.

PFU, plaque-forming units.
References
  1. TUDRIQEV™ Safety Data Sheet. Replimune, Inc. Updated September 22, 2026. Accessed October 2, 2026. https://replimune-group.files.svdcdn.com/production/general/1175-0001-Rev.-04-TUDRIQEV-Safety-Data-Sheet-approved.pdf?dm=1790610794
  2. TUDRIQEV™ Prescribing Information. Replimune, Inc.; 2026.
  3. Data on file. Replimune, Inc.; 2026.